Self-assembling modified β-cyclodextrin nanoparticles as neuronal sirna delivery vectors: focus on huntington’s disease.

The effect of particle design on cellular internalization pathways

Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · see citing works

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,508 · see citing works

Toxicity of cationic lipids and cationic polymers in gene delivery

Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286 · see citing works

Nanocarriers’ entry into the cell: relevance to drug delivery

Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,549 · see citing works

The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic

Davis, M. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900015y · Cited by 979 · see citing works

Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease

Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · see citing works

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · see citing works

Chemically modified siRNA: tools and applications

Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431 · see citing works

Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

DiFiglia, M., Sena‐Esteves, M., Chase, K. O., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708285104 · Cited by 417 · see citing works

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382 · see citing works

Engineering RNA for Targeted siRNA Delivery and Medical Application

Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 301 · see citing works

Stability of Self-Assembled Polymeric Micelles in Serum

Lu, J., Owen, S. C., & Shoichet, M. S. (2011) · Macromolecules · doi:10.1021/ma200675w · Cited by 299 · see citing works

Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice

Rodríguez-Lebrón, E., Denovan‐Wright, E. M., Nash, K. R., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 277 · see citing works

Nonviral methods for siRNA delivery

Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244 · see citing works

Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat

Tan, P.-H., Yang, L.-C., Hc, S., Lan, K.-C., & Cheng, J.-T. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302376 · Cited by 222 · see citing works

A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery

Lu, J. J.-Q., Langer, R., & Chen, J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900023v · Cited by 219 · see citing works

Highly Efficient Small Interfering RNA Delivery to Primary Mammalian Neurons Induces MicroRNA-Like Effects before mRNA Degradation

Davidson, T. J., Harel, S., Arboleda, V. A., Prunell, G., Shelanski, M. L., Greene, L. A., & Troy, C. M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3643-04.2004 · Cited by 215 · see citing works

The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

Li, J. Y., Popović, N., & Brundin, P. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.447 · Cited by 211 · see citing works

Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference

Thakker, D. R., Natt, F., Hüsken, D., Maier, R., Müller, M., van der Putten, H., Hoyer, D., & Cryan, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406214101 · Cited by 211 · see citing works

Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA

Wang, Y., Liu, W., Wada, E., Murata, M., Wada, K., & Kanazawa, I. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.06.021 · Cited by 192 · see citing works

RNAi functions in cultured mammalian neurons

Krichevsky, A. M., & Kosik, K. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182272699 · Cited by 175 · see citing works

siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain

Thakker, D. R., Natt, F., Hüsken, D., van der Putten, H., Maier, R., Hoyer, D., & Cryan, J. F. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001687 · Cited by 159 · see citing works

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153 · see citing works

Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles

Wong, Y., Markham, K., Xu, Z. P., Chen, M., Lu, G. Q., Bartlett, P. F., & Cooper, H. M. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.077 · Cited by 152 · see citing works

Functional Delivery of siRNA in Mice Using Dendriworms

Agrawal, A., Min, D., Singh, N., Zhu, H., Birjiniuk, A., von Maltzahn, G., Harris, T. J., Xing, D., Woolfenden, S. D., Sharp, P. A., et al. (2009) · ACS Nano · doi:10.1021/nn900201e · Cited by 147 · see citing works

Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain

Kim, I., Lim, C., Kim, J., Nam, H. Y., Nam, K., Kim, S.-W., Park, J., & Lee, J.-K. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.011 · Cited by 131 · see citing works

Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice

Guo, J., Ogier, J. R., Desgranges, S., Darcy, R., & O’Driscoll, C. M. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.012 · Cited by 127 · see citing works

A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference

Lombardi, M. S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Maria, E. D., Donato, S. D., & Kaemmerer, W. F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.004 · Cited by 124 · see citing works

Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review

Chaturvedi, K., Ganguly, K., Kulkarni, A. R., Kulkarni, V. H., Nadagouda, M. N., Rudzinski, W. E., & Aminabhavi, T. M. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.610790 · Cited by 110 · see citing works

Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons

Tönges, L., Lingor, P., Egle, R., Dietz, G. P. H., Fahr, A., & Bähr, M. (2006) · RNA · doi:10.1261/rna.2252206 · Cited by 103 · see citing works

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

Guo, J., Fisher, K. A., Darcy, R., Cryan, J. F., & O’Driscoll, C. M. (2010) · Molecular BioSystems · doi:10.1039/c001050m · Cited by 97 · see citing works

Therapeutic potential of RNA interference for neurological disorders

Sah, D. W. Y. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.06.011 · Cited by 97 · see citing works

Widespread suppression of huntingtin with convection-enhanced delivery of siRNA

Stiles, D. K., Zhang, Z., Ge, P., Nelson, B. D., Grondin, R., Ai, Y., Hardy, P., Nelson, P. T., Guzaev, A. P., Butt, M. T., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.020 · Cited by 91 · see citing works

Tf-lipoplexes for neuronal siRNA delivery: A promising system to mediate gene silencing in the CNS

Cardoso, A. L., Simões, S., de Almeida, L. P., Plesnila, N., de Lima, M. C. P., Wagner, E., & Culmsee, C. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.014 · Cited by 86 · see citing works

Local Knockdown of Genes in the Brain Using Small Interfering RNA: A Phenotypic Comparison with Knockout Animals

Salahpour, A., Medvedev, I. O., Beaulieu, J., Gainetdinov, R. R., & Caron, M. G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.020 · Cited by 80 · see citing works

CAG repeat lengths ≥ 335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse

Dragatsis, I., Goldowitz, D., Mar, N. D., Deng, Y. P., Meade, C. A., Liu, L., Sun, Z., Dietrich, P., Yue, J., & Reiner, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.009 · Cited by 78 · see citing works

Click-Modified Cyclodextrins as Nonviral Vectors for Neuronal siRNA Delivery

O’Mahony, A., Godinho, B. M. D. C., Ogier, J. R., Devocelle, M. C., Darcy, R., Cryan, J. F., & O’Driscoll, C. M. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000372 · Cited by 75 · see citing works

Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells

Neill, M. J. O., Guo, J., Byrne, C. J., Darcy, R., & O’Driscoll, C. M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.021 · Cited by 71 · see citing works

A click chemistry route to 2-functionalised PEGylated and cationic β-cyclodextrins: co-formulation opportunities for siRNA delivery

O’Mahony, A., Ogier, J. R., Desgranges, S., Cryan, J. F., Darcy, R., & O’Driscoll, C. M. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob25490e · Cited by 70 · see citing works

Comprehensive Behavioral Testing in the R6/2 Mouse Model of Huntington's Disease Shows No Benefit from CoQ10 or Minocycline

Menalled, L., Patry, M., Ragland, N., Lowden, P. A. S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J. M., Howland, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009793 · Cited by 70 · see citing works

Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats

Fiszer, A., Mykowska, A., & Krzyżosiak, W. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr156 · Cited by 69 · see citing works

Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery

Chen, Q., Butler, D., Querbes, W., Pandey, R. K., Ge, P., Maier, M. A., Zhang, L., Rajeev, K. G., Nechev, L. V., Koteliansky, V., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.02.011 · Cited by 67 · see citing works

Therapeutic Gene Silencing Delivered by a Chemically Modified Small Interfering RNA against Mutant SOD1 Slows Amyotrophic Lateral Sclerosis Progression

Wang, H., Ghosh, A., Baigude, H., Yang, C., Qiu, L., Xia, X., Zhou, H., Rana, T. M., & Xu, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800834200 · Cited by 66 · see citing works

A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroventricular injection of a novel chemically modified siRNA in the adult rat brain

Nakajima, H., Kubo, T., Semi, Y., Itakura, M., Kuwamura, M., Izawa, T., Azuma, Y., & Takeuchi, T. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.10.003 · Cited by 63 · see citing works

Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi

Snøve, O., & Rossi, J. J. (2006) · Genome biology · doi:10.1186/gb-2006-7-8-231 · Cited by 54 · see citing works

Gold Nanorod–siRNA Induces Efficient In Vivo Gene Silencing in The Rat Hippocampus

Bonoiu, A. C., Bergey, E. J., Ding, H. Y., Hu, R., Kumar, R., Yong, K., Prasad, P. N., Mahajan, S. D., Picchione, K. E., Bhattacharjee, A., et al. (2011) · Nanomedicine · doi:10.2217/nnm.11.20 · Cited by 54 · see citing works

RNAi therapeutics for CNS disorders

Boudreau, R. L., & Davidson, B. L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.038 · Cited by 52 · see citing works

Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins

Mcmahon, A., O’Neill, M. J., Gómez‐Orte, E., Donohue, R., Forde, D., Darcy, R., & O’Driscoll, C. M. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01497.x · Cited by 44 · see citing works

siRNA Delivery to CNS Cells using a Membrane Translocation Peptide

Ifediba, M. A., Medarova, Z. O., Ng, S., Yang, J., & Moore, A. V. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900488e · Cited by 36 · see citing works

Gene Therapy: A Primer for Neurosurgeons

Chiocca, E. (2003) · Neurosurgery · doi:10.1227/01.neu.0000073532.05714.2b · Cited by 21 · see citing works

A Note on Regulatory Concerns and Toxicity Assessment in Lipid-Based Delivery Systems (LDS)

Souto, E. B., Martins‐Lopes, P., Lopes, C. M., Gaivão, I., Silva, A. M., & Guedes‐Pinto, H. (2009) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2009.1041 · Cited by 19 · see citing works

Erratum: Progress and prospects: immune responses to viral vectors

Nayak, S., & HERZOG, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.168 · Cited by 2 · see citing works

Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs

Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works

Cyclodextrin complexes: Perspective from drug delivery and formulation

Jacob, S., & Nair, A. B. (2018) · Drug Development Research · doi:10.1002/ddr.21452 · Cited by 263 · see citing works

Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives

Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B. H., & Anjum, I. (2021) · Pharmaceuticals · doi:10.3390/ph14080707 · Cited by 258 · see citing works

Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

Poovaiah, N., Davoudi, Z., Peng, H., Schlichtmann, B. W., Mallapragada, S. K., Narasimhan, B., & Wang, Q. (2018) · Nanoscale · doi:10.1039/c8nr04073g · Cited by 227 · see citing works

A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer

Sun, D., Zou, Y., Song, L., Han, S., Yang, H., Chu, D., Dai, Y., Ma, J., O’Driscoll, C. M., Yu, Z., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.005 · Cited by 197 · see citing works

Current Advances in The Development of Novel Polymeric Nanoparticles for The Treatment of Neurodegenerative Diseases

Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144 · see citing works

Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance

Carthy, D. J. M., Malhotra, M., O’Mahony, A., Cryan, J. F., & O’Driscoll, C. M. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1545-6 · Cited by 132 · see citing works

A Vision for Cyclodextrin Nanoparticles in Drug Delivery Systems and Pharmaceutical Applications

Lakkakula, J., & Krause, R. W. M. (2014) · Nanomedicine · doi:10.2217/nnm.14.41 · Cited by 130 · see citing works

Neurotheranostics as Personalized Medicines

Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

Coisne, C., Tilloy, S., Monflier, É., Wils, D., Fénart, L., & Gosselet, F. (2016) · Molecules · doi:10.3390/molecules21121748 · Cited by 120 · see citing works

Cyclodextrin-based nanostructures

Narayanan, G., Shen, J., Matai, I., Sachdev, A., Boy, R., & Tonelli, A. E. (2021) · Progress in Materials Science · doi:10.1016/j.pmatsci.2021.100869 · Cited by 119 · see citing works

The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics

Fitzgerald, K. A., Guo, J., Tierney, E. G., Curtin, C. M., Malhotra, M., Darcy, R., O’Brien, F. J., & O’Driscoll, C. M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.019 · Cited by 112 · see citing works

Cyclodextrins in drug delivery: applications in gene and combination therapy

Haley, R. M., Gottardi, R., Langer, R., & Mitchell, M. J. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00724-5 · Cited by 109 · see citing works

Cyclodextrins, Blood–Brain Barrier, and Treatment of Neurological Diseases

Vecsernyés, M., Fenyvesi, F., Bácskay, I., Deli, M. A., Szente, L., & Fenyvesi, É. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.020 · Cited by 102 · see citing works

Cyclodextrin-based nanoparticles for pharmaceutical applications: a review

Pandey, A. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01275-y · Cited by 94 · see citing works

Silica Nanoparticles and Polyethyleneimine (PEI)-Mediated Functionalization: A New Method of PEI Covalent Attachment for siRNA Delivery Applications

Kapilov-Buchman, Y., Lellouche, E., Zigdon, S., Bechor, M., Michaeli, S., & Lellouche, J. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4004316 · Cited by 92 · see citing works

Nano-Assemblies of Modified Cyclodextrins and Their Complexes with Guest Molecules: Incorporation in Nanostructured Membranes and Amphiphile Nanoarchitectonics Design

Zerkoune, L., Angelova, A., & Lesieur, S. (2014) · Nanomaterials · doi:10.3390/nano4030741 · Cited by 91 · see citing works

A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor

Fitzgerald, K. A., Malhotra, M., Gooding, M., Sallas, F., Evans, J. C., Darcy, R., & O’Driscoll, C. M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.055 · Cited by 81 · see citing works

Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system

McCarthy, J., O'Neill, M. J., Bourré, L., Walsh, D. P., Quinlan, A., Hurley, G., Ogier, J. R., Shanahan, F., Melgar, S., Darcy, R., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.004 · Cited by 74 · see citing works

Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System

Mendonça, M. C. P., Kont, A., Aburto, M. R., Cryan, J. F., & O’Driscoll, C. M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01238 · Cited by 73 · see citing works

Efficient targeted pDNA/siRNA delivery with folate–low-molecular-weight polyethyleneimine–modified pullulan as non-viral carrier

Wang, J., Dou, B., & Bao, Y. (2013) · Materials Science and Engineering C · doi:10.1016/j.msec.2013.08.035 · Cited by 72 · see citing works

Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy

Guo, J., Russell, E. G., Darcy, R., Cotter, T. G., McKenna, S. L., Cahill, M. R., & O’Driscoll, C. M. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01150 · Cited by 70 · see citing works

Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics

Zhang, Y., Zou, Z., Liu, S., Miao, S., & Liu, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.954470 · Cited by 69 · see citing works

Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: In vitro analysis

Gooding, M., Malhotra, M., McCarthy, D. J., Godinho, B. M. D. C., Cryan, J. F., Darcy, R., & O’Driscoll, C. M. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.02.007 · Cited by 68 · see citing works

Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases

Riccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., & Melone, M. A. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111897 · Cited by 66 · see citing works

Multifunctional Nanotheranostics for Overcoming the Blood–Brain Barrier

Beygi, M. H. M., Oroojalian, F., Azizi‐Arani, S., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202310881 · Cited by 65 · see citing works

Nanomaterial applications for neurological diseases and central nervous system injury

Huang, L., Hu, J., Huang, S., Wang, B. Z., Siaw-Debrah, F., Nyanzu, M. K., Zhang, Y., & Zhuge, Q. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.003 · Cited by 65 · see citing works

Molecular nanoparticle-based gene delivery systems

Blanco, J. L. J., Benito, J. M., Mellet, C. O., & Fernández, J. M. G. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.03.012 · Cited by 63 · see citing works

Triblock Copolymer Nanovesicles for pH-Responsive Targeted Delivery and Controlled Release of siRNA to Cancer Cells

Gallon, E., Matini, T., Sasso, L., Mantovani, G., Armiñán, A., Sanchis, J., Caliceti, P., Alexander, C., Vicent, M. J., & Salmaso, S. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00286 · Cited by 62 · see citing works

Self-Assembled Cationic β-Cyclodextrin Nanostructures for siRNA Delivery

Singh, R. P., Hidalgo, T., Cazade, P., Darcy, R., Cronin, M. F., Dorin, I., O’Driscoll, C. M., & Thompson, D. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01307 · Cited by 61 · see citing works

A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer

Zou, Y., Xiao, F., Song, L., Sun, B., Sun, D., Chu, D., Wang, L., Han, S., Yu, Z., O’Driscoll, C. M., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120888 · Cited by 59 · see citing works

siRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery

Gomes, M. J., Martins, S., & Sarmento, B. F. C. C. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.03.001 · Cited by 59 · see citing works

Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition

James, E. N., Delany, A. M., & Nair, L. S. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.04.026 · Cited by 59 · see citing works

Surfactants influence polymer nanoparticle fate within the brain

Joseph, A., Simo, G. M., Gao, T. A., Alhindi, N., Xu, N., Graham, D. J., Gamble, L. J., & Nance, E. A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121086 · Cited by 58 · see citing works

Recent advances in cyclodextrin delivery techniques

Arima, H., Hayashi, Y., Higashi, T., & Motoyama, K. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1026893 · Cited by 57 · see citing works

Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo

Evans, J. C., Malhotra, M., Guo, J., O’Shea, J. P., Hanrahan, K., O’Neill, A., Landry, W. D., Griffin, B. T., Darcy, R., Watson, R. W. G., et al. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.06.014 · Cited by 56 · see citing works

Gene delivery based on macrocyclic amphiphiles

Geng, W., Huang, Q., Xu, Z., Wang, R., & Guo, D. (2019) · Theranostics · doi:10.7150/thno.31914 · Cited by 56 · see citing works

Non-Viral Nanosystems for Gene and Small Interfering RNA Delivery to the Central Nervous System: Formulating the Solution

O’Mahony, A., Godinho, B. M. D. C., Cryan, J. F., & O’Driscoll, C. M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23672 · Cited by 55 · see citing works

Nanotechnology for Neurodegenerative Diseases: Recent Progress in Brain-Targeted Delivery, Stimuli-Responsive Platforms, and Organelle-Specific Therapeutics

Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52 · see citing works

PEGylated cyclodextrins as novel siRNA nanosystems: Correlations between polyethylene glycol length and nanoparticle stability

Godinho, B. M. D. C., Ogier, J. R., Quinlan, A., Darcy, R., Griffin, B. T., Cryan, J. F., & O’Driscoll, C. M. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.054 · Cited by 52 · see citing works

A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders

Mazibuko, Z., Choonara, Y. E., Kumar, P., du Toit, L. C., Modi, G., Naidoo, D., & Pillay, V. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24322 · Cited by 51 · see citing works

Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders

Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49 · see citing works

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00184 · Cited by 49 · see citing works

Delivering a disease-modifying treatment for Huntington's disease

Godinho, B. M. D. C., Malhotra, M., O’Driscoll, C. M., & Cryan, J. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.011 · Cited by 47 · see citing works

Nanotechnology in Drug Discovery and Development

Gutiérrez, L., Stepien, G., Gutiérrez, L., Pérez-Hernández, M., Pardo, J., Pardo, J., Grazú, V., & de la Fuente, J. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12292-9 · Cited by 46 · see citing works

Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model

Mendonça, M. C. P., Cronin, M. F., Cryan, J. F., & O’Driscoll, C. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.11.003 · Cited by 46 · see citing works

Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer

Sun, Y., Cronin, M. F., Mendonça, M. C. P., Guo, J., & O’Driscoll, C. M. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106427 · Cited by 46 · see citing works

Prospects for neuroprotective therapies in prodromal Huntington's disease

Chandra, A., Johri, A., & Beal, M. F. (2014) · Movement Disorders · doi:10.1002/mds.25835 · Cited by 41 · see citing works

Short interfering RNA therapeutics: nanocarriers, prospects and limitations

Mehrotra, N., & Tripathi, R. M. (2015) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2015.0018 · Cited by 41 · see citing works

Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system

Godinho, B. M. D. C., McCarthy, D. J., Torres‐Fuentes, C., Beltrán, C. J., McCarthy, J., Quinlan, A., Ogier, J. R., Darcy, R., O’Driscoll, C. M., & Cryan, J. F. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.068 · Cited by 39 · see citing works

Medical and Nonmedical Applications of Synthetic Transmembrane Anion Transporters

Rathnaweera, U. M. C., Chowdhury, S. M., Salam, R., & Busschaert, N. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00129 · Cited by 38 · see citing works

Oligonucleotide-based therapy for neurodegenerative diseases

Magen, I., & Hornstein, E. (2014) · Brain Research · doi:10.1016/j.brainres.2014.04.005 · Cited by 38 · see citing works

Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?

Guo, J., Evans, J. C., & O’Driscoll, C. M. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.02.002 · Cited by 38 · see citing works

Cyclodextrin-siRNA conjugates as versatile gene silencing agents

Malhotra, M., Gooding, M., Evans, J. C., O’Driscoll, D., Darcy, R., & O’Driscoll, C. M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.11.024 · Cited by 38 · see citing works

siRNA delivery for treatment of degenerative diseases, new hopes and challenges

Zahir‐Jouzdani, F., Mottaghitalab, F., Dinarvand, M., & Atyabi, F. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.04.001 · Cited by 37 · see citing works

pH-Responsive Polymersome Microparticles as Smart Cyclodextrin-Releasing Agents

Puglisi, A., Bayır, E., Tımur, S., & Yağcı, Y. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01083 · Cited by 36 · see citing works

Cyclodextrin-Based Functional Glyconanomaterials

Rivero-Barbarroja, G., Benito, J. M., Mellet, C. O., & Fernández, J. M. G. (2020) · Nanomaterials · doi:10.3390/nano10122517 · Cited by 35 · see citing works

Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours

Evans, J. C., Malhotra, M., Sweeney, K. G., Darcy, R., Nelson, C. C., Hollier, B. G., & O’Driscoll, C. M. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.013 · Cited by 35 · see citing works

Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna Delivery

O’Mahony, A., Ogier, J. R., Darcy, R., Cryan, J. F., & O’Driscoll, C. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066413 · Cited by 34 · see citing works

Strategies and materials of "SMART" non-viral vectors: Overcoming the barriers for brain gene therapy

Li, Y., Liu, L., Ji, W., Peng, H., Zhao, R., & Zhang, X. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101006 · Cited by 33 · see citing works

Non-Viral Nucleic Acid Delivery Strategies to the Central Nervous System

Tan, J. Y., Sellers, D. L., Pham, B., Pun, S. H., & Horner, P. J. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00108 · Cited by 33 · see citing works

M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy

Sun, Y., Cronin, M. F., Mendonça, M. C. P., Guo, J., & O’Driscoll, C. M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00769 · Cited by 32 · see citing works

Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment

Ribeiro, T. D. C., Sábio, R. M., Carvalho, G. C., Fonseca‐Santos, B., & Chorilli, M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121978 · Cited by 32 · see citing works

Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro

Evans, J. C., McCarthy, J., Torres‐Fuentes, C., Cryan, J. F., Ogier, J. R., Darcy, R., Watson, R. W. G., & O’Driscoll, C. M. (2015) · Gene Therapy · doi:10.1038/gt.2015.50 · Cited by 28 · see citing works

Cyclodextrin as a singular oligosaccharide: Recent advances of health benefit and in food applications

Sevim, S., & Şanlıer, N. (2024) · Journal of Food Science · doi:10.1111/1750-3841.17527 · Cited by 27 · see citing works

“Click” chemistry mediated construction of cationic curdlan nanocarriers for efficient gene delivery

Han, J., Wang, X., Liu, L., Li, D., Suyaola, S., Wang, T., & Baigude, H. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.01.055 · Cited by 26 · see citing works

Potential Therapeutic Application of dendrimer/cyclodextrin Conjugates With Targeting Ligands As Advanced Carriers for Gene and Oligonucleotide Drugs

Arima, H., Motoyama, K., & Higashi, T. (2017) · Therapeutic Delivery · doi:10.4155/tde-2016-0064 · Cited by 23 · see citing works

Revisiting gene delivery to the brain: silencing and editing

Conniot, J., Talebian, S., Simões, S. M. N., Ferreira, L., & Conde, J. (2020) · Biomaterials Science · doi:10.1039/d0bm01278e · Cited by 23 · see citing works

Incontinence products and devices for the elderly.

Newman, D. K. (2004) · PubMed · Cited by 23 · see citing works

Nanobiotechnology in Neurodegenerative Diseases

Jampílek, J., Kráľová, K., Novák, P., & Novák, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_4 · Cited by 22 · see citing works

Endogenous microRNA triggered enzyme-free DNA logic self-assembly for amplified bioimaging and enhanced gene therapy via in situ generation of siRNAs

Jiang, Q., Yue, S., Yu, K., Tian, T., Zhang, J., Chu, H., Cui, Z., & Bi, S. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01040-x · Cited by 22 · see citing works

Theranostical application of nanomedicine for treating central nervous system disorders

Wang, R., & Xue, X. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9292-7 · Cited by 22 · see citing works

Cyclodextrins as Active Therapeutic Agents: Beyond Their Role as Excipients

Pîrvu, A. S., Văruţ, R.-M., Trașcă, D.-M., Stoica, G. A., Radivojević, K., Carmen, S., Arsenie, C. C., & Popescu, C. (2025) · Pharmaceuticals · doi:10.3390/ph18101592 · Cited by 21 · see citing works

Engineered Self-Assembly of Amphiphilic Cyclodextrin Conjugates for Drug Encapsulation

Brettner, F. E. B., Schreiner, J., Vogel‐Kindgen, S., & Windbergs, M. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01023 · Cited by 21 · see citing works

Nontoxic, Biodegradable Hyperbranched Poly(β-amino ester)s for Efficient siRNA Delivery and Gene Silencing

Ooi, Y. J., Huang, C., Lau, K., Chew, S. Y., Park, J. G., & Chan‐Park, M. B. E. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c10620 · Cited by 20 · see citing works

Application of Nanomaterials in Neurodegenerative Diseases

Cui, W., Fu, W., Lin, Y., & Zhang, T. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666200326093410 · Cited by 20 · see citing works

Co-Formulation of Amphiphilic Cationic and Anionic Cyclodextrins Forming Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukaemia

Kont, A., Mendonça, M. C. P., Cronin, M. F., Cahill, M. R., & O’Driscoll, C. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179791 · Cited by 19 · see citing works

Cyclodextrin-Containing Drug Delivery Systems and Their Applications in Neurodegenerative Disorders

Xing, Y., Meng, B., & Chen, Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910834 · Cited by 19 · see citing works

A biodegradable adamantane polymer with ketal linkages in its backbone for gene therapy

Maity, S., Choudhary, P., Manjunath, M., Kulkarni, A., & Murthy, N. (2015) · Chemical Communications · doi:10.1039/c5cc05242d · Cited by 18 · see citing works

Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin

Mendonça, M. C. P., Sun, Y., Cronin, M. F., Lindsay, A. J., Cryan, J. F., & O’Driscoll, C. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020520 · Cited by 18 · see citing works

Focusing the pivotal role of nanotechnology in Huntington’s disease: an insight into the recent advancements

Singh, S., Hema, Sharma, N., Sachdeva, M., Behl, T., Zahoor, I., Fuloria, N. K., Sekar, M., Fuloria, S., Subramaniyan, V., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22830-2 · Cited by 17 · see citing works

Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process

Escalona-Rayo, O., Fuentes-Vázquez, P., Leyva‐Gómez, G., Cisneros, B., Villalobos, R., Magaña, J. J., & Quintanar‐Guerrero, D. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1281949 · Cited by 17 · see citing works

Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders

Singh, D., Kapahi, H., Rashid, M., Prakash, A. K., Majeed, A. B. A., & Mishra, N. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1029622 · Cited by 17 · see citing works

Lipid nanoparticle mediated small interfering RNA delivery as a potential therapy for Alzheimer's disease

Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 16 · see citing works

Gastrointestinal gene delivery by cyclodextrins – In vitro quantification of extracellular barriers

O’Neill, M. J., O’Mahony, A., Byrne, C. J., Darcy, R., & O’Driscoll, C. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.08.073 · Cited by 16 · see citing works

A new approach for a blood-brain barrier model based on phospholipid vesicles: Membrane development and siRNA-loaded nanoparticles permeability

Gomes, M. J., Dreier, J., Brewer, J. R., Martins, S., Brandl, M., & Sarmento, B. F. C. C. (2016) · Journal of Membrane Science · doi:10.1016/j.memsci.2016.01.002 · Cited by 15 · see citing works

Advances in nanotherapeutic strategies for Huntington's disease: Design, delivery, and neuroprotective mechanisms

Khan, S., Bano, N., Ahamad, S., Dar, N. J., Nazir, A., & Bhat, S. A. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216206 · Cited by 14 · see citing works

Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders

Nguyen, T. T., Nguyen‐Thi, P., Nguyen, T. H. A., Ho, T.-T., An, T. N. M., Toi, V. V., & Giau, V. V. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00654-1 · Cited by 14 · see citing works

Biophysical and Structural Characterisation of Nucleic Acid Complexes with Modified Cyclodextrins Using Circular Dichroism

O’Mahony, A., Cronin, M. F., Mcmahon, A., Evans, J. C., Daly, K., Darcy, R., & O’Driscoll, C. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23922 · Cited by 14 · see citing works

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Borbolla‐Jiménez, F. V., Prado-Audelo, M. L. D., Cisneros, B., Caballero-Florán, I. H., Leyva‐Gómez, G., & Magaña, J. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071018 · Cited by 13 · see citing works

β-Cyclodextrin-based polyelectrolyte complexes for drug delivery

Zhao, R., Tang, B., Xu, Z., & Fang, G. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216581 · Cited by 12 · see citing works

Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases

Lee, L. K. C., Leong, L. I., Liu, Y., Luo, M., Chan, H. Y. E., & Choi, C. H. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00506 · Cited by 12 · see citing works

Innovation in nanomedicine: nanocarriers for central nervous system disorders management

Waqar, M. A., Mubarak, N., Khan, A. M., Ahmad, S., Zaib, M., Kanwal, U., Khan, I. N., Ayesha, M., Mughal, M., & Fahad, M. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2024.2399271 · Cited by 11 · see citing works

Tetraethylenepentamine-Coated β Cyclodextrin Nanoparticles for Dual DNA and siRNA Delivery

Liu, C., Shih, P.-Y., Lin, C.-H., Chen, Y.-J., Wu, W., & Wang, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050921 · Cited by 11 · see citing works

Polymeric nanotherapeutics: An emerging therapeutic approach for the management of neurodegenerative disorders

Chakraborty, P., Bhattacharyya, C., Sahu, R., Dua, T. K., Kandimalla, R. J. L., & Dewanjee, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105267 · Cited by 11 · see citing works

RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies

Malhotra, M., Toulouse, A., Godinho, B. M. D. C., Carthy, D. J. M., Cryan, J. F., & O’Driscoll, C. M. (2015) · Molecular BioSystems · doi:10.1039/c5mb00278h · Cited by 8 · see citing works

RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials

Hsia, T., & Chen, Y. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114234 · Cited by 7 · see citing works

Small RNA drugs for prion disease: a new frontier

Boese, A. S., Majer, A., Saba, R., & Booth, S. A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.818976 · Cited by 7 · see citing works

Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives

Khawaja, S., Ali, R. H., Ahmed, I., & Umair, M. (2025) · Current Genomics · doi:10.2174/0113892029361490250310041259 · Cited by 6 · see citing works

Bioinspired and Biomimetic Systems: Cell–Derived Vesicles as Drug Carriers for Targeted Delivery in Neurodegenerative Disorders

Holghoomi, R., Rahdar, A., Kadkhoda, J., Mohammadzadeh, V., Shirzad, M., Salehi, B., Ebrahimi, M.-S., & Pandey, S. (2026) · Nano LIFE · doi:10.1142/s179398442630013x · Cited by 6 · see citing works

Modified cyclodextrins as novel non-viral vectors for neuronal siRNA delivery: focus on Huntington’s disease

Godinho, B. M. D. C. (2014) · Cork Open Research Archive (University College Cork, Ireland)

Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model

Mendonça, M. C. P., Cronin, M. F., Cryan, J. F., & O’Driscoll, C. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.11.003 · Cited by 46 · see citing works

Click-Modified Cyclodextrins as Nonviral Vectors for Neuronal siRNA Delivery

O’Mahony, A., Godinho, B. M. D. C., Ogier, J. R., Devocelle, M. C., Darcy, R., Cryan, J. F., & O’Driscoll, C. M. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000372 · Cited by 75 · see citing works

Self-assembling Modified β -cyclodextrin Conjugated siRNA Nanoparticles and Liposomal siRNA Efficiently Knock Down the Mutant Huntingtin Gene in a Modified PC-12 Cell Line

Ladi, R., DAS, S. K., & Das, N. R. (2015) · Digital Commons @ Butler University (Butler University)

Iron Oxide Nanoparticle-Mediated siRNA Delivery System for Huntington’s Disease Treatment

Rohiwal, S. S., Nguyen, T. D., Kamenná, E., Klı́ma, J., Vaškovičová, M., Sekac, D., Šlouf, M., Pavlová, E., Stepanek, P., Babuka, D., et al. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c03936 · Cited by 16 · see citing works